Predictive biomarkers for EGFR tyrosine kinase
inhibitors in treatment of advanced non-small-cell lung cancer: a
systematic review and meta-analysis of randomised controlled trials
ZY Yang1, C Mao1, DY Zheng2,
JL Tang1
1 Division of Epidemiology, The
Jockey Club School of Public Health and Primary Care, The Chinese
University of Hong Kong
2 Department of Oncology, Nanfang
Hospital, Southern Medical University, Guangzhou, Guangdong Province,
China
1. Of the four potential predictive biomarkers
studied, epidermal growth factor receptor (EGFR) gene mutations are
the most powerful predictor of the efficacy of EGFR tyrosine kinase
inhibitors in advanced non-small-cell lung cancer. They should be tested
prior to treatment to select patients who are more likely to benefit from
EGFR tyrosine kinase inhibitors.
2. Chemotherapy is a better choice than EGFR tyrosine kinase inhibitors in patients with wild-type EGFR.
2. Chemotherapy is a better choice than EGFR tyrosine kinase inhibitors in patients with wild-type EGFR.